Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-Drug dependence is not physical dependence alone, nor is it the same as drug tolerance. "Drug dependence is primarily psychological dependence, or compulsive use of drugs for their mood-altering effects and continued use despite harm," David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

VANCOUVER, BC-Drug dependence is not physical dependence alone,nor is it the same as drug tolerance. "Drug dependence isprimarily psychological dependence, or compulsive use of drugsfor their mood-altering effects and continued use despite harm,"David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

The WHO Expert Committee on Drug Dependence recently clarifiedthat a cancer patient who has been receiving opioids for painand who stops the drug would go through a withdrawal syndromeas evidence of physical dependence, but that individual is notconsidered to be drug dependent.

"Physical dependence by itself is no longer sufficient todefine drug dependence or addiction," Mr. Joranson said."It is important for us to teach this and to clear up themythology about the relationship between opioid analgesia andaddiction."

Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
Related Content